Clarivate: The Data Intelligence Company Flying Under the Radar

Core Insights - Clarivate (CLVT) is a data intelligence company with a share price of $2.64 and a market cap of $1.67 billion, generating significant free cash flow and focusing on its core data assets in intellectual property and academic research [1] Financial Performance - In 2025, Clarivate generated $628.5 million in operating cash flow despite a net loss of $201.1 million, primarily due to $757.2 million in depreciation and amortization from past acquisitions [1] - The company reported free cash flow of $365.3 million for the full year and is guiding for $365 million to $435 million in 2026 [1] Strategic Initiatives - Clarivate is actively selling its Life Sciences and Healthcare segment to reduce its $4.47 billion debt load, with CEO Matti Shem Tov emphasizing the importance of this move for focusing on the A&G and IP market [1] - The sale proceeds from the Life Sciences and Healthcare segment could significantly improve the company's leverage situation [1] AI Integration - Clarivate views AI as an amplifier of its business model rather than a threat, integrating its regulatory intelligence platform with Anthropic's Claude to enhance its offerings [1] - The company maintains a strong revenue mix, with 97% coming from proprietary solutions and 88% being recurring revenue, creating a competitive moat [1] Market Position - Despite being largely unnoticed by mainstream investors, Clarivate's data assets are critical for researchers, patent attorneys, and pharmaceutical scientists, positioning the company as an essential player in its niche [1] - The stock has declined by 39% over the past year, with future performance dependent on the outcome of the LS&H sale, the pace of deleveraging, and the impact of AI on its business [1]